Download
Download by
Scanning QR Code
  • Download app

    Download app

  • Online Inquiry

    Log in to access Online Inquiry
+
Congratulations
You've successfully got advanced quotes worth 5000 HKD
Download APP >>
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data

NTLA Intellia Therapeutics

Watchlist
43.150
+0.710+1.67%
Close  02/01 16:00 ET
43.350
+0.200+0.46%
Post Mkt Price 02/01 19:34 ET
High
43.730
Open
43.710
Turnover
51.44M
Low
40.900
Pre Close
42.440
Volume
1.21M
Market Cap
3.68B
P/E(TTM)
Loss
52wk High
104.870
Shares
85.23M
P/E(Static)
Loss
52wk Low
32.435
Float Cap
3.46B
Bid/Ask %
0.00%
Historical High
202.730
Shs Float
80.25M
Volume Ratio
1.05
Historical Low
9.180
Dividend TTM
--
Div Yield TTM
--
P/B
4.12
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
1.51%
Amplitude
6.67%
Avg Price
42.561
Lot Size
1
Float Cap
3.46B
Bid/Ask %
0.00%
Historical High
202.730
Shs Float
80.25M
Volume Ratio
1.05
Historical Low
9.180
Dividend TTM
--
P/B
4.12
Dividend LFY
--
Turnover Ratio
1.51%
Amplitude
6.67%
Avg Price
42.561
Lot Size
1
Price Forecast

News

Comment

Company Overview More
Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.
CEO: Mr. John M. Leonard, M.D.
Market: NASDAQ
Listing Date: 05/06/2016
Futu Hot List
USHKCN
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist